DaeHwa Pharmaceutical shares hit the upper price limit (the daily price increase cap) in early trading on the 8th. The rise followed news that DaeHwa Pharmaceutical's anticancer drug was added to China's National Reimbursement Drug List.
As of 9:17 a.m. on the 8th, DaeHwa Pharmaceutical stock on the KOSDAQ market was up 29.89% (5,730 won) from the previous trading day to 24,900 won.
According to the industry, on the same day, DaeHwa Pharmaceutical's oral paclitaxel anticancer drug Liporaxel solution was newly included in the 2025 National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA). Reimbursement will take effect starting Jan. 1 next year.
※ This article has been translated by AI. Share your feedback here.